Tanir, F.; Mete, B.; Demirhindi, H.; Kara, E.; Nazlican, E.; Dağlıoğlu, G.; Kibar, F.; Çetiner, S.; Kanat, C. Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study. Vaccines2022, 10, 1177.
Tanir, F.; Mete, B.; Demirhindi, H.; Kara, E.; Nazlican, E.; Dağlıoğlu, G.; Kibar, F.; Çetiner, S.; Kanat, C. Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study. Vaccines 2022, 10, 1177.
Tanir, F.; Mete, B.; Demirhindi, H.; Kara, E.; Nazlican, E.; Dağlıoğlu, G.; Kibar, F.; Çetiner, S.; Kanat, C. Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study. Vaccines2022, 10, 1177.
Tanir, F.; Mete, B.; Demirhindi, H.; Kara, E.; Nazlican, E.; Dağlıoğlu, G.; Kibar, F.; Çetiner, S.; Kanat, C. Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study. Vaccines 2022, 10, 1177.
Abstract
This prospective cohort study aimed to evaluate the efficacy of COVID-19 vaccine schemes, ho-mologous versus heterologous vaccine strategies, and vaccine-induced anti-S-RBD-IgG antibody response in preventing COVID-19 among 942 healthcare workers one year after vaccination with the inactivated and/or mRNA vaccines. All participants received the first two primary doses of vaccines, 13.6% of them lacked the dose-3, 50.5% the dose-4, and 90.3% the dose-5. Antibody lev-els increased with the increase in number of vaccine doses and also in heterologous vaccine regi-mens. In both inactive and mRNA vaccines, infection rates were significantly higher in 2-dose-receivers, but lower in 4- or 5-dose receivers and increasing the total number of vaccine doses resulted in more protection against infection: the 3-dose regimen yielded 4.71 times more protection, the 4-dose 11.76 times and 5-dose 38.46 times more protection from COVID-19 infec-tion, compared to any 2-dose vaccination regimens. Antibody levels at the end of the first year of 4- or 5-dose-receivers were significantly higher than 2- or 3-dose-receivers. To conclude; increased number of total vaccine doses and anti-S-RBD antibody levels increased the protection from COVID-19 infection. Therefore, four or more doses are recommended in one year, for effective protection, especially in risk groups.
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.